


The discussion related to these products has changed dramatically from those had in previous years; in the past, the industry was discussing the regulatory framework and how the different regulatory agencies, from Mexico to Argentina, would regulate these new therapeutic options. Now, after the maturity of the laws and the construction of different regulatory pathways for biosimilars in most of the countries, the discussion has moved on to the different challenges that the industry, whether local or foreign, faces in commercializing biosimilars.
In most of the countries, governments are promoting the introduction of the biosimilars, due in part to the constraints they face in paying for high-cost innovative biologics, in addition to controlling healthcare spending linked with the increasing prevalence of diseases like cancer, diabetes, and other chronic conditions.
In the coming years, we will see a dynamic market with many players moving between countries with different regulatory frameworks and health system compositions, all trying to survive deep price reductions while demonstrating added value through the development of more real-world evidence or benefits in product improvements. At the same time, we will see these players increasing patient access to medicines. In the end, patients will benefit from these market dynamics with the introduction of therapeutic options that can help to overcome the access disparities that our region currently has.
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
From these areas:
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speaker Board

Julio Cesar Vega
Laboratorio Pablo Cassará, Argentina
R&D Manager
R&D Manager

Luis Reyes
LEI, Mexico
Head of Quality Assurance Preclinical Unit
Head of Quality Assurance Preclinical Unit

Jane Finzi
Waters, Brazil
Market Development Lead
Market Development Lead

Eart Cruz
Teva Pharmaceuticals, Peru
Senior Manager Regulatory Affairs
Senior Manager Regulatory Affairs

John E. Feliciano Alfonso
National University of Colombia, Colombia
Clinical Pharmacologist and Clinical Epidemiologist, University Professor
Clinical Pharmacologist and Clinical Epidemiologist, University Professor

Nicolas Alberto Costa
Sandoz, Argentina
Head Medical Affairs - Argentina, Chile, Uruguay & Paraguay
Head Medical Affairs - Argentina, Chile, Uruguay & Paraguay

Fabio Aristizabal
Universidad Nacional de Colombia, Colombia
Senior Associate Professor
Senior Associate Professor

Carlos Dominguez
Synthon, Mexico
General Manager
General Manager

Alvaro León Torres
Dempos, Colombia
Director of Pharmaceutical Care
Director of Pharmaceutical Care

Gilberto Castañeda
Department of Pharmacology of the Center for Research and Advanced Studies of the National Polytechnic Institute (IPN), Mexico
Researcher
Researcher

Carlos Ochoa
Previs IPS, Colombia
Laboratory Lead Microbiologist
Laboratory Lead Microbiologist

Diana Bernal
Universidad del Rosario, Colombia
Associate Professor
Associate Professor

Angela Caro
Asociación Colombiana de Farmacovigilancia, Colombia
President
President

Carlos Felipe Escobar Roa
INNOS, Colombia
Director
Director

Ximena Marcela Bonilla Forero
IDCBIS, Colombia
Research Leader Pharmaceutical Biotechnology Unit
Research Leader Pharmaceutical Biotechnology Unit

Enrique Alvarez
Sartorius, Mexico
Central America, Caribbean & VECO Sub Region Manager
Central America, Caribbean & VECO Sub Region Manager

Iván Darío Agudelo Zapata
Senate, Colombia
Senator of the Republic
Senator of the Republic

Julian Molina
CEDSS, Colombia
Scientific Director
Scientific Director

Giancarlo Videla Yarlequé
Marken, Peru
Senior Specialist in Clinical and Pharmaceutical Logistic Operations
Senior Specialist in Clinical and Pharmaceutical Logistic Operations

Fernando Carmona
Cytiva, Argentina
Upstream and Cell Culture Sales Specialist
Upstream and Cell Culture Sales Specialist

Guillermo Pardo
Laboratorios Legrand, Colombia
VP Operations & COO
VP Operations & COO

Nicolas Estrada
Merck, Mexico
Single-use Customer Applications
Single-use Customer Applications

Paola Fletscher
Amgen, Colombia
Compliance Senior Manager
Compliance Senior Manager

Sean McGowan
Amerisource Bergen, USA
Biosimilars, Pharmaceutical Commercialization
Biosimilars, Pharmaceutical Commercialization

Fernando Goicoechea Romero
Goicoechea & Associates, Mexico
General Manager LatAm
General Manager LatAm

Cristina Ausin
FDA, USA
Scientific Reviewer
Scientific Reviewer

Patricia Socualaya Sotomayor
Ministry of Health - DIGEMID, Peru
Chief Officer at Biological Product Unit
Chief Officer at Biological Product Unit

Mauricio Rubio
Suanfarma, Colombia
Country Manager Colombia
Country Manager Colombia

Ricardo Castro
Saya Bio, Mexico
VP of Bioprocessing
VP of Bioprocessing
Program at a Glance
Looking Back to Biosimilars in FDA
Beginning of the regulatory framework for Biosimilars in these agencies
Private Initiatives for Biosimilars Development
The advances that laboratories have made in Colombia
Challenges for innovation
What does it take to introduce innovative drugs in Latam
Proper communication between Companies and Healthcare Professionals
Recommendations for a healthy and clear communication
Biosimilars success stories
Experiences from companies in other countries that can help the Colombian industry
Communication of Regulatory Agencies in Latam
The requirements and suggestions from ANMAT and DIGEMID
Biosimilars post-Pandemic
What is expected to happen once the pandemie is over
Full programme in the PDF Agenda
Download Agenda

Sponsors
Photo Gallery from Previous Events
